Physician profile
Brad Leath
NPI 1093169195
$616.37
in general payments reported to CMS, 2019-2025
12 companies · $311 in 2025
The $311 reported for 2025 was more than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $23.83 · 2024: $282 · 2025: $311.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $616.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $616.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Organon LLC | $107.86 | 2023-2025 | Nexplanon |
| Sumitomo Pharma America, INC. | $102.41 | 2025 | Myfembree, Gemtesa |
| Hologic Sales and Service, LLC | $81.91 | 2024-2025 | Aptima, Novasure |
| Coopersurgical, INC. | $52.98 | 2024-2025 | Summit Doppler, Paragard T 380a, Endosee |
| Exeltis, USA INC. | $48.58 | 2024-2025 | Slynd |
| Biogen, INC. | $44.40 | 2024-2025 | Zurzuvae |
| Astellas Pharma US INC | $40.15 | 2024-2025 | Veozah |
| Abbvie INC. | $38.77 | 2024 | |
| Shield Therapeutics INC | $32.58 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $27.28 | 2025 | |
| Mindray Ds USA, INC. | $21.72 | 2025 | Te7 Max, Te X |
| Solventum Corporation | $17.73 | 2025 | Prevena |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brad Leath listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.